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ABSTRACT
COMPARISON AND APPLICATION OF METHODS TO ADDRESS CONFOUNDING BY INDICATION
IN NON-RANDOMIZED CLINICAL STUDIES
SEPTEMBER 2013
CHRISTINE M FOLEY, B.S., WORCESTER STATE UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Raji Balasubramanian

Objective: The aim of this project was to apply and compare marginal structural models, and
propensity score adjusted models with traditional Cox Proportional Hazards models to address
confounding by indication due to the presence of time-dependent confounders. These methods
were applied to data from approximately 120,000 women enrolled in the Women’s Health
Initiative (WHI) to evaluate the causal effect of antidepressant medication use with respect to
type 2 diabetes risk.

Methods: Four approaches were compared. Three traditional Cox Models were used. The first
used only baseline covariates. The second used time-varying antidepressant medication use,
BMI and presence of elevated depressive symptoms and adjusted for all other covariates
measured at baseline. The third used time-varying antidepressant medication use, BMI and
presence of elevated depressive symptoms and adjusted for other baseline covariates, with
additional adjustment for propensity to taking antidepressants at baseline. Our fourth method
used a Marginal Structural Cox Model with Inverse Probability of Treatment Weighting that
included time-varying antidepressant medication use, BMI and presence of elevated depressive
symptoms and adjusted for all other covariates measured at baseline.
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Results: All approaches showed an increase in diabetes risk for those taking antidepressant
medication. The Cox Proportional Hazards models using only baseline covariates showed the
lowest increase in risk (OR=1.21, 95% CI 1.07 - 1.36; OR=1.16, 95% CI 1.02 - 1.32, respectively).
Diabetes risk increased with adjustment for time-dependent confounding and results for these
three approaches were almost identical. All models were statistically significant. Ninety-five
percent confidence intervals overlapped for all 4 approaches showing they were not significantly
different from one another.

Conclusions: Our analyses did not find a difference in estimates between traditional Cox
Proportional Hazards Models and Marginal Structural Cox Models in the WHI cohorts. Estimates
of the Inverse Probability of Treatment Weights were all very close to 1 which explains why we
observed similar results with all four approaches.

Keywords: Antidepressant medication, type 2 diabetes, epidemiology, marginal structural
models, propensity score, survival analysis

iv

TABLE OF CONTENTS

Page
ABSTRACT…………………………………………………………………………………………………….…iii
LIST OF TABLES………………………………………………………………………..……………………..vii
LIST OF FIGURES…………………………………………………………………….……..……………….viii
CHAPTER
I.

INTRODUCTION…………………………………………………………………………………….…………1

II.

METHODS…………………………………………………………………………………………….………….4
The Women’s Health Initiative (WHI)…………………………………………………….………..4
Outcome Ascertainment……………………………………………………………………….………..4
Time-Varying Exposure………………………………………………………………..………….…...5
Time-Varying Confounders………………………………………………………….………….…...5
Other Confounders……………………………………………………………………….…….…………6

III.

STATISTICAL ANALYSIS……………………………………………………………………….…………..7
Analysis Datasets………………………………………………………………………………….….…….7
Approach 1 – Cox Proportional Hazards Model……………………………………….…….8
Approach 2 – Extended Cox Proportional Hazards Model………………………….….8
Approach 3 – Extended Cox Proportional Hazards Model Adjusting for
Propensity……………………………………………………………………………………….…...……….8
Approach 4 – Marginal Structural Cox Proportional Hazards Model……..….…..9

v

Page
IV.

RESULTS………………………………………………………………………………………………………….12

V.

DISCUSSION……………………………………………………………………………………………………15

APPENDIX - SAS CODE TO FIT THE MARGINAL STRUCTURAL COX PROPORTIONAL HAZARDS
MODEL………………………………………………………………………………………….…………………………….28
REFERENCES………………………………………………………………………….……………………………………33

vi

LIST OF TABLES

Table

Page

1.

Summary of Baseline Characteristics of the Study Sample…………..……………17

2.

Hazard Ratios Comparing Cox Proportional Hazards Models to Marginal
Structural Models………………………………………………………………………………………20

3.

Inverse Probability of Treatment-Weighted Estimates Of The Parameters Of
A Marginal Structural Model For The Causal Effect Of Antidepressant
Medication Use On Diabetes Risk………………………………………..…..………………21

4.

Estimated Probability of Having One’s Own Observed Treatment History
And Censoring History At Follow- ………………………………………….…………………24

5.

Estimate of Variation in Primary Exposure and Time-Dependent Confounder
Variables (WHI-OS).…………………………….……………………….…………..………………25

vii

LIST OF FIGURES

Figure
1.

Page
Illustration of time-dependent confounding by BMI in the association of
antidepressant medication use and time to development of diabetes………………26

2.

Flow chart describing analytic cohort included for the investigation………………….27

viii

CHAPTER I
INTRODUCTION

Diabetes is a chronic illness with serious health consequences, such as adult blindness,
non-traumatic limb amputation, renal failure and neuropathy. Previous literature has noted
considerable diabetes and depression among postmenopausal women, with a prevalence rate
that is approximately 12% for each. 1, 2 As many as 25% of individuals live with both conditions. 3
Two separate meta-analyses demonstrated that adults with depression had a 37-60% increased
risk of developing diabetes. 4, 5 The 2009 sub-analysis of the Melbourne Longitudinal Studies on
Healthy Ageing (MELSHA) found that symptomatic depression predicts a 2-fold increase in
diabetes incidence, with or without antidepressant use. 6
Recent literature suggests an increased risk of diabetes among those who are depressed
and on antidepressant medications. 7-10 It is increasingly important to further investigate
whether depression or the antidepressant medication is influencing this association given that
approximately 11% of American women take antidepressant medication, and use is rising. 11
While the rates of use for depression treatment has remained the same, off-label use of
antidepressants has increased significantly. 12 Examples of antidepressant off-label use include
treatment for certain type of pain, fibromyalgia, insomnia, and general unhappiness.
The Women’s Health Initiative (WHI) database is a valuable resource that can inform the
association between antidepressant medication use/depression and diabetes risk in a
population of post-menopausal women. It is a longitudinal study with a large sample size
containing repeated measurements for presence of elevated depressive symptoms, selfreported diagnosis of type 2 diabetes and antidepressant medication use.
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Ma and colleagues
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found that elevated depressive symptoms and antidepressant

medication use were significantly related to type 2 diabetes risk in both unadjusted and
multivariable Cox models in the WHI. However, the WHI is a non-randomized setting in which
there is the potential for several time-dependent confounders such as BMI to influence the
causal relationship between antidepressant use and diabetes risk (Figure 1). In other words,
participants with increased BMI or depression could be more likely to be on antidepressants in
the future. Moreover, BMI and depression can also significantly influence future diabetes risk.
Thus, a naïve analysis to evaluate the causal relationship between antidepressant use and
diabetes risk could result in biased estimates of the effects of antidepressant medication use by
misattributing the effects of time-dependent confounders such as BMI to treatment.
When research interest lies in the causal effect of a time varying exposure on outcome,
in the presence of time-modified confounding, traditional Cox models can result in biased
estimates that do not necessarily have causal interpretation (Figure 1). 14-16 In an observational
study, it is difficult to guarantee balance of important potential confounding variables such as
age, race/ethnicity, and gender between groups because participants were not randomized to
either antidepressant medication users or non-users. If more participants in one level of the
confounding variable are on treatment because of the influence of a time-dependent
confounder, we could falsely see a treatment effect when there is not one. A solution to this
problem is the use of marginal structural models. Marginal structural models are appropriate
when you have time-dependent confounding with a time-varying exposure. They aim to break
the association between the exposure and confounder and provide balance between treatment
and control across levels of the confounding variable. These methods can also be applied if your
time-dependent confounder is influenced by prior treatment and is thus an intermediate.
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The objective of this work was to apply and compare results obtained from standard
approaches, such as multivariable Cox models and propensity score adjusted Cox models to
those obtained from the application of IPTW marginal structural model methods developed for
causal inference applicable to non-randomized settings. These methods were applied to data
from approximately 68,000 women enrolled in the WHI-OS and approximately 52,000 women
enrolled in the WHI-CT to evaluate the causal effect of antidepressant medication use with
respect to type 2 diabetes risk.
The paper is organized as follows: In the Methods section, we describe our study
population, timing of our measurements, instruments used and our modeling approaches. We
also describe our outcome measures, along with time varying exposures and confounders
considered. In the Results section, we present results obtained by applying the four approaches
we used to estimate the causal effect of antidepressant medication use on development of
diabetes. In the Discussion section, we compare and contrast our results with the results of
other investigators who have used similar approaches in different applications. Our analyses
contribute to the comparison of these models to standard techniques as it applies to the
analysis of large scale epidemiological models and non-randomized observational studies.
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CHAPTER II
METHODS

The Women’s Health Initiative (WHI)
The WHI enrolled 161,808 participants into clinical trials (WHI-CT) and an observational
study (WHI-OS) between 1993 and 1998. 17-20 The eligibility criteria included: postmenopausal
women aged 50 to 79 years, reliable/mentally competent, and expected survival and local
residency for at least 3 years. Exclusion criteria included current alcoholism, drug dependency,
and dementia or other conditions that would limit full participation in the study. The WHI
enrolled 68,132 participants into clinical trials (WHI-CT), and 93,676 women were enrolled into
an observational study (WHI-OS). 17 The WHI-CT included: the Dietary Modification Trial (DMT),
the Hormone Trial (HT, estrogen-alone or estrogen plus progestin) and the combination of DMT
and HT. Participants enrolled in one of the clinical trial components were screened for eligibility
and invited to join the calcium and vitamin D (CaD) component at their first or second annual
clinic visits. Medication use, presence of elevated depressive symptoms, and diabetes status
were collected from participants over an average of 7.6 years of follow-up. The study was
approved by the institutional review boards of participating WHI institutions, and institutional
review board exemption for the current investigation was obtained at the University of
Massachusetts Medical School.
Outcome Ascertainment
The outcome variables in our analysis were diabetes status and time to development of
diabetes. Diabetes status was assessed by self-report at baseline and at each annual follow-up
visit. Time to diabetes was calculated as the interval between study enrollment and
development of diabetes as evidenced by an annual medical history update, or censorship
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(death or end of study participation). Margolis and colleagues 21 found patient self-report of
diabetes to be a reliable indicator of diagnosed diabetes, validated with medication and
laboratory data assessments.
Time Varying Exposure
Our main exposure of interest was antidepressant medication use, measured at
baseline and year 3 in the WHI-OS and baseline, year 1, year 3, year 6 and year 9 in the WHI-CT
arm. Medication use was collected using the F44 Medication form, at which time case
managers transcribed label information from medication bottles brought in by the WHI
participants. Antidepressants include the following major groups: 1) Selective serotonin
reuptake inhibitors (SSRIs); 2) Monoamine oxidase inhibitors (MAOIs); 3) Tricyclic
antidepressants (TCAs); 4) Tetracyclics; 5) Serotonin/norepinephrine reuptake inhibitors (SNRIs);
6) Aminoketones; 7) Triazolopyridines; and 8) Dibenzoxazepine. A dichotomous indicator of
antidepressant medication use was then created. 13 We did not perform any analyses by class of
medication.
Time Varying Confounders
The primary time varying confounders considered in this analysis were (1) presence of
elevated depressive symptoms and (2) BMI. Elevated depressive symptoms were measured
using the 6-item Center for Epidemiological Studies Depression Scale (CES-D). A participant was
determined to have elevated depressive symptoms if their score was 5 or higher on the CES-D.
Presence of elevated depressive symptoms was available at baseline and year 3 in the WHI-OS.
In the WHI-CT, presence of elevated depressive symptoms was assessed in a small percentage of
participants after baseline. For this reason, analysis for this cohort adjusted only for presence of
elevated depressive symptoms at baseline. BMI was available at baseline and year 3 in the WHIOS and baseline, year 1, year 3, year 6 and year 9 in the WHI-CT.
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Other confounders
Models adjusted for age, race/ethnicity (White vs. Other), education (<=high school; high
school or GED; >= high school, but less than 4 years of college; 4 or more years of college),
minutes of recreational physical activity per week, total energy intake, hormone therapy use
(never, former, current), family history of diabetes (no, yes, don’t know) and smoking status
(never smoked, past smoker, current smoker), all measured at baseline. Many of these could
have potentially been time-varying if we had repeated measurements.
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CHAPTER III
STATISTICAL ANALYSIS

Analysis datasets
WHI OS
A total of 68,169 women were available for analysis in this cohort after exclusions for
self-reported diagnosis of diabetes at baseline (n=3902), missing baseline diabetes status
(n=109), missing race/ethnicity information (n=252), or missing information on presence of
elevated depressive symptoms (n=10,427), antidepressant medication use or BMI (n=6899) at
baseline or year 3 (Figure 2). After exclusions, a total of 3624 women reported diagnosis of type
2 diabetes during follow-up. Information on the time-varying exposure (antidepressant use) and
the time varying confounders (BMI, presence of elevated depressive symptoms) were available
at baseline and year 3.
WHI CT
Although we had data from baseline to year 9 in the WHI-CT, we used data from
baseline to year 3 for this analysis because presence of elevated depressive symptoms was only
measured on a small percentage of women after year 1. The time-varying exposure
(antidepressant use) and the time varying confounder (BMI) were available at baseline, year 1
and year 3. Models adjusted for presence of elevated depressive symptoms at baseline.
Women were excluded from analysis if they had a self-reported diagnosis of diabetes at baseline
(n=3265), missing diabetes status at baseline (n=36), or missing race/ethnicity information
(n=125). We also excluded women who were missing information on baseline presence of
elevated depressive symptoms (n=531), antidepressant medication use or BMI at baseline, year

7

1 or year 3 (n=11,849) (Figure 2), resulting in 52,326 women available for analysis. After
exclusions, a total of 4171 women reported diagnosis of type 2 diabetes during follow-up.
We compared results from 4 different approaches in estimating the association
between presence of elevated depressive symptoms and antidepressant medication use with
the risk of type 2 diabetes. We used three traditional Cox Proportional Hazards Models
(Approaches 1-3) and a Marginal Structural Cox Model (Approach 4) to estimate the association
in the WHI-OS and WHI-CT separately.
Approach 1 - Cox Proportional Hazards Model
Approach 1 used traditional Cox Proportional Hazards Models to estimate the
association of antidepressant medication use at baseline on diabetes risk, adjusting for baseline
factors including: presence of elevated depressive symptoms, BMI, age, ethnicity, education,
minutes of recreational physical activity per week, total energy intake, hormone therapy use,
family history of diabetes and smoking status.
Approach 2 - Extended Cox Proportional Hazards Model
Approach 2 used an extended Cox Model to model the association of time-varying
antidepressant medication use on diabetes risk adjusting for time-varying presence of elevated
depressive symptoms (WHI-OS) or baseline presence of elevated depressive symptoms (WHICT), time-varying BMI, and adjusted for age, ethnicity, education, minutes of recreational
physical activity per week, total energy intake, hormone therapy use, family history of diabetes
and smoking status, all measured at baseline.
Approach 3 - Extended Cox Proportional Hazards Model Adjusting for Propensity
Approach 3 used an extended Cox Model with time-varying exposure and confounders,
as in Approach 2, with additional adjustment for propensity to taking antidepressants at
baseline. The time-invariant propensity score was calculated by predicting baseline
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antidepressant use from a logistic model that included presence of elevated depressive
symptoms, BMI, age, ethnicity, education, minutes of recreational physical activity per week,
total energy intake, hormone therapy use, family history of diabetes and smoking status, all
measured at baseline.
Approach 4 – Marginal Structural Cox Proportional Hazards Model
We followed the basic framework of Hernan and colleagues
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for fitting marginal

structural models for survival analysis by estimating the IPTW weights. Four logistic regression
models were used to calculate the probabilities that constructed the weights. Models 1 and 2
estimated the probability of not being on antidepressants. To account for the effect of
censoring, models 3 and 4 estimated the probability of not being censored. Each model was
adjusted for the following confounders: age, ethnicity, education, minutes of recreational
physical activity per week, total energy intake, hormone therapy use, family history of diabetes
and smoking status, all measured at baseline. In the WHI-CT analysis, models were also
adjusted for which clinical trial a woman was participating in. The numerator of the weight is a
function of baseline covariates. The denominator used the same baseline covariates, and added
the most recent time-varying value as well. To relax the linearity assumption, we added a
quadratic function of time, month and month2, as additional covariates in the model.
Estimating the probability of not being on antidepressants – Models 1 and 2
Using a dataset with one row of data per participant per measurement time point, we
estimated the probability of not being on antidepressant medication at each time point as a
function of presence of elevated depressive symptoms and BMI, as well as other confounders.
Model 1 estimated the probability of not being on antidepressants as a function of baseline
covariates. Model 2 included baseline covariates, as well as the most recent value of the timevarying covariates.
9

Estimating the probability of not being censored – Models 3 and 4
We used a dataset expanded to one row of data per participant for each month until
their time to diabetes because censoring was a time to event outcome. A woman who did not
develop diabetes had 1 row of data per month until they were censored. In the last row of data
for each woman, their censoring or diabetes indicator was equal to 1, and equal to 0 in all rows
previous. In this way, the time to diabetes or time to censoring indicator for each woman was
utilized. The probability of not being censored was estimated as a function of antidepressant
medication use, presence of elevated depressive symptoms, BMI, and other confounders.
Model 3 estimated the probability of not being censored as a function of baseline covariates.
Model 4 included baseline covariates, as well as the most recent value of the time-varying
covariates.
Estimating subject- and time-specific stabilizing weights
Models 1-4 were merged together and the weights were calculated. The IPTW are
calculated as a cumulative product that multiplies the probability of antidepressant medication
use over time for each participant. The probability for each patient remains constant over time
until there is a new measurement point and then that probability is multiplied by the new
probability. Since the probability of not being censored was a time to event outcome, we
calculated the cumulative product over all months for each participant. The numerator of the
stabilizing weights was calculated as the probability of antidepressant use multiplied by the
probability of being uncensored for each participant for each month. The denominator of the
stabilizing weights was calculated in the same manner, and the ratio of the two was the
stabilizing weight.
Marginal Structural Cox Model
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The final step in our analysis was to run a pooled logistic regression model using the PROC
GENMOD procedure in SAS as a way to fit the weighted Cox model. 14 An independent working
correlation matrix was specified in the model. The model was weighted by the stabilized IPTW
estimates. This procedure produced hazard ratios for the risk of diabetes for those using
antidepressant medications compared to those who were not. The pooled logistic regression
model estimated the association as a function of time-varying antidepressant medication use,
time-varying presence of elevated depressive symptoms (OS) or baseline presence of elevated
depressive symptoms (CT), time-varying BMI, and other confounders. To relax the linearity
assumption with respect to time, we included both a linear and quadratic function of time, as
additional covariates in the model.
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CHAPTER IV
RESULTS

Table 1 presents the baseline characteristics of our study population, by antidepressant
medication use. In both cohorts, the mean age was approximately 63 years old (63.59 (OS);
62.77 (CT)). Women were primarily White (86.5% (OS); 84.4% (CT)) and most had greater than
high school education (80% (OS); 76.4% (CT)). Approximately 30% of women on antidepressants
had elevated depressive symptoms (28.2% (OS); 29.8% (CT)). A greater percentage of
antidepressant medication users than non-users reported current use of hormone replacement
therapy (64.9% vs. 49.7% (OS); 53.6% vs. 36.3% (CT)). Antidepressant users and non-users had
approximately equal proportions that reported a family history of diabetes (30% vs. 30.6% (OS);
31.4% vs. 31.6% (CT)) or current smoking (7.2% vs. 5.4% (OS); 9.0% vs. 7.2% (CT)). Mean BMI
was very similar for those on antidepressants vs. not (27.91 vs. 26.70 (OS); 29.41 vs. 28.48 (CT)).
Table 2 presents development of diabetes for those who were exposed to
antidepressant medication compared to those who were not for all 4 modeling approaches. The
Cox PH model including only baseline antidepressant medication use and baseline presence of
elevated depressive symptoms produced a crude diabetes rate ratio of 1.26 (95% CI 1.12-1.41)
indicating a significant increase in diabetes risk without adjusting for other factors. The standard
Cox model in Approach 1 does not adjust for time-dependent confounding and yielded a hazard
ratio of 1.21 (95% CI 1.07 – 1.36) in the OS cohort. The Cox models in Approach 2 and Approach
3 using time-varying antidepressant medication use, time-varying presence of elevated
depressive symptoms and time-varying BMI, yielded almost identical results (HR=1.33, 95% CI
1.20-1.48; HR=1.31; 95% CI 1.17 - 1.45, respectively) and showed an increased risk of developing
diabetes relative to Approach 1. The hazard ratio and confidence interval for the marginal
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structural Cox model (Approach 4) was almost identical to the extended Cox models in Approach
2 and Approach 3 (HR=1.34; 95% CI 1.20 - 1.50) demonstrating that, in this application, the
marginal structural Cox model yielded similar results to the traditional extended Cox model. The
confidence intervals for all 4 models overlap indicating the models are not significantly different
than one another.
As in the WHI OS, all models in the WHI-CT showed a significant increase in diabetes risk
for those exposed to antidepressant medications vs. those who were not. The crude diabetes
rate ratio (HR=1.17, 95% CI 1.04-1.31) was very similar to the results in Approach 1. The hazard
ratios and confidence intervals for Approaches 2, 3, and 4 were almost identical, and like the OS
cohort the risk estimate is greater than in Approach 1, which did not adjust for time-dependent
confounding (HR: 1.16;95% CI 1.02-1.32). By adjusting for time-dependent confounding, the
hazard ratios for Approach 2 and Approach 3 increased from Approach 1 (HR=1.28, 95% CI 1.141.43; HR=1.26, 95% CI 1.12-1.41, respectively). The marginal structural model in Approach 4
again estimated a hazard ratio almost identical to that of the extended Cox models (HR=1.27,
95% CI 1.13-1.43). The confidence intervals for all 4 models overlap, indicating they are not
significantly different from one another.
Table 3 presents the full model inverse probability of treatment-weighted estimates for
the marginal structural models for the causal effect of antidepressant medication use on
diabetes risk. All covariates including antidepressant medication use, ethnicity, education,
minutes of physical activity per week, family history of diabetes, hormone therapy use, smoking
status, presence of elevated depressive symptoms, BMI, age, and total energy intake are
significant in the model for the WHI-OS, and all but total energy intake for the WHI-CT.
Table 4 presents the distributions of the IPTW weights, namely the estimated
probability of having one’s own observed treatment history and censoring history at follow-up
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time points. The probability of remaining uncensored was very close to 1 for both cohorts at
each follow-up time point given both the baseline and time-varying covariates. There was
variation in the probability of having one’s own observed treatment history, but the mean and
median were very close to 1 at 36 month follow-up in the WHI-OS and 12 month follow-up in
the WHI-CT.
Table 5 presents an estimate of variation in the primary exposure and time-dependent
confounder variables. Participants not on antidepressants remained pretty stable over time, but
there was some switching on and off the drug. Of the 60,297 participants who were not taking
antidepressants at baseline, 95% of them were also not taking them at year 3. Of the 3,321
participants who were taking antidepressants at baseline, 69.35% of them were also taking
them at year 3. Approximately 30% of those who were on antidepressants at baseline were not
taking them at year 3 and almost 5% of those not taking them at baseline were on
antidepressants at year 3.
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CHAPTER V
DISCUSSION

We compared Marginal Structural Cox Proportional Hazards Models to standard Cox
Models to estimate the association of antidepressant medication use and presence of elevated
depressive symptoms on diabetes risk in the WHI. Previous research has shown a marginal
structural modeling approach to be an unbiased method when you have a time-varying
confounder, such as BMI, that is affected by previous exposure.
Our analyses did not find a difference in estimates between traditional Cox Proportional
Hazards Models and Marginal Structural Cox Models in the WHI cohorts. The hazard ratios and
confidence intervals for the 4 models we compared in the WHI OS and the 4 models we
compared in the WHI CT were all very similar. As our models increased in complexity, first
taking into account the time-varying confounding (Cox PH Models) and then time-dependent
confounding (Marginal Structural Models), the estimates were very similar to the crude rate
ratio. This suggests that the time-varying confounders did not have much effect on our
outcome. The confidence intervals overlapped, indicating they were not significantly different
from one another. Our estimates of the IPTW weights were all very close to 1 which drives the
observed similarity in results using marginal structural models when compared to Cox
Proportional Hazards Models.
A limitation of this work is that we had a limited amount of measurement points to work
with in this dataset. The WHI-OS had 2 measurement time points. The WHI-CT had more time
points available, but we were only able to utilize 3 of them because of insufficient numbers of
participants with enough data for our main exposure variable after baseline. This allowed for
long periods of time where we had no new information on their antidepressant medication use,
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BMI, presence of elevated depressive symptoms, or other covariates. We may have missed
important information on our time-varying exposure or covariates during that time. Participants
could have gone off antidepressants 1 year after enrolling in the study, but we would not have
accounted for that until year 3 when we had new data on that subject. Participants could also
have gone off antidepressants and then gone back on during the period of time where we did
not have new data. Because presence of elevated depressive symptoms was measured on only
a small percentage of participants after baseline, our models for the WHI-CT could not use
presence of elevated depressive symptoms as a time varying exposure.
Our analyses contribute to the literature by demonstrating that marginal structural
models may not be required over traditional methods of analysis in all applications. A certain
level of time-dependent confounding may need to exist in your dataset for these complicated
methods to be called for. An important area for further study would be to assess what level of
time-dependent confounding is necessary for marginal structural models to be a better
approach than standard methods.
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Table 1. Summary of Baseline Characteristics of the Study Sample
(Continued on to next few pages)

No

Antidepressant Medication Use
Yes
WHI-OS

BMI
Mean (SD)
26.70 (5.48)
27.91 (5.97)
Median (IQR)
25.64 (6.32)
26.74 (7.19)
Age
Mean (SD)
63.70 (7.26)
62.14 (7.25)
Median (IQR)
64 (11)
62 (12)
Minutes of recreational physical activity per week
Mean (SD)
206.93 (186.19)
172.12 (174.80)
Median (IQR)
165 (225)
135 (212.5)
Years from enrollment to developing diabetes
Mean (SD)
7.69 (1.47)
7.56 (1.54)
Median (IQR)
7.93 (1.99)
7.88 (2.00)
Total energy intake
Mean (SD)
1533.05 (599.86)
1615.08 (640.37)
Median (IQR)
1461.29 (730.06)
1533.19 (765.75)
Presence of elevated depressive symptoms
No
54923 (86.7%)
3440 (71.8%)
Yes
8457 (13.3%)
1349 (28.2%)
Ethnicity
White
54614 (86.2%)
4380 (91.5%)
Other
8766 (13.8%)
409 (8.5%)
Education
<= high school
2409 (3.8%)
189 (4%)
High school or GED
9765 (15.5%)
752 (15.9%)
>=High school, but less
than 4 years of college
22587 (35.9%)
1765 (37.2%)
4 or more years of
college
28152 (44.7%)
2036 (42.9%)
Hormone therapy use
Never
18423 (29.6%)
738 (15.7%)
Former
12885 (20.7%)
914 (19.4%)
Current
30931 (49.7%)
3055 (64.9%)
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Total

26.79 (5.53)
25.71 (6.39)
63.59 (7.27)
64 (11)
204.48 (185.63)
165 (225)
7.68 (1.47)
7.92 (1.99)
1538.82 (603.16)
1465.41 (733.40)
58363 (85.6%)
9806 (14.4%)
58994 (86.5%)
9175 (13.5%)
2598 (3.8%)
10517 (15.5%)
24352 (36%)
30188 (44.6%)
19161 (28.6%)
13799 (20.6%)
33986 (50.8%)

No

Antidepressant Medication Use
Yes

Total

Family history of diabetes
No
Yes
Don't know
Smoking status
Never Smoked
Past Smoker
Current Smoker

41656 (66%)
18923 (30%)
2569 (4.1%)

3114 (65.2%)
1463 (30.6%)
198 (4.1%)

44770 (65.9%)
20386 (30%)
2767 (4.1%)

32614 (52%)
26685 (42.6%)
3370 (5.4%)

2188 (46.2%)
2207 (46.6%)
339 (7.2%)

34802 (51.6%)
28892 (42.9%)
3709 (5.5%)

WHI-CT
BMI
Mean (SD)
28.48 (5.64)
29.41 (5.99)
Median (IQR)
27.57 (7.20)
28.35 (7.96)
Age
Mean (SD)
62.83 (6.93)
61.77 (6.94)
Median (IQR)
63 (11)
61 (11)
Minutes of recreational physical activity per week
Mean (SD)
163.22 (168.95)
138.94 (159.22)
Median (IQR)
125 (215)
85 (195)
Years from enrollment to developing diabetes
Mean (SD)
7.99 (1.68)
7.86 (1.73)
Median (IQR)
8.02 (1.73)
8.00 (1.91)
Total energy intake
Mean (SD)
1716.72 (679.54)
1819.65 (711.86)
Median (IQR)
1618.25 (832.50)
1716.34 (870.79)
Presence of elevated depressive symptoms
No
42582 (86.7%)
2238 (70.2%)
Yes
6557 (13.3%)
949 (29.8%)
Ethnicity
White
41243 (83.9%)
2924 (91.7%)
Other
7896 (16.1%)
263 (8.3%)
Education
<= high school
2302 (4.7%)
144 (4.5%)
High school or GED
8991 (18.4%)
587 (18.5%)
>=High school, but less
than 4 years of college
19110 (39.1%)
1236 (39%)
4 or more years of
college
18426 (37.7%)
1199 (37.9%)
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28.54 (5.67)
27.62 (7.23)
62.77 (6.94)
63 (11)
161.72 (168.47)
120 (215)
7.98 (1.68)
8.02 (1.76)
1723.00 (682.00)
1623.68 (833.68)
44820 (85.7%)
7506 (14.3%)
44167 (84.4%)
8159 (15.6%)
2446 (4.7%)
9578 (18.4%)
20346 (39.1%)
19625 (37.7%)

No

Antidepressant Medication Use
Yes

Total

Hormone therapy use
Never used hormones
Past hormone user
Current hormone user
Family history of diabetes
No
Yes
Don't know
Smoking status
Never Smoked
Past Smoker
Current Smoker

17793 (37.9%)
12122 (25.8%)
17057 (36.3%)

662 (21.6%)
760 (24.8%)
1644 (53.6%)

18455 (36.9%)
12882 (25.7%)
18701 (37.4%)

31282 (63.9%)
15378 (31.4%)
2280 (4.7%)

2022 (63.7%)
1004 (31.6%)
147 (4.6%)

33304 (63.9%)
16382 (31.4%)
2427 (4.7%)

25547 (52.5%)
19615 (40.3%)
3495 (7.2%)

1429 (45.2%)
1445 (45.7%)
285 (9%)

26976 (52.1%)
21060 (40.6%)
3780 (7.3%)
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Table 2. Hazard Ratios Comparing Cox Proportional Hazards Models to Marginal Structural
Models
Observational Cohort (OS) (N=68,169 - the number of patients with complete data for time
varying antidepressant medication use, presence of elevated depressive symptoms, and BMI
up until year 3, and baseline values for other covariates)
Crude Diabetes
Approach 1
Approach 2
Approach 3
Approach 4
Rate Ratio
Cox PH Model
Cox PH Models Cox PH Models
Cox PH Models
Marginal
(using baseline
(using baseline
(using time
(using time
Structural Models
antidepressant
values of all
varying
varying
(using time
medication use
predictors)
antidepressant
antidepressant
varying
and baseline
medication use,
medication use,
antidepressant
presence of
medication use,
presence of
presence of
elevated
presence of
elevated
elevated
depressive
elevated
depressive
depressive
symptoms)
depressive
symptoms,
symptoms, and
and BMI;
baseline values
for other
covariates)
Predictor
Antidepressant
medication use
up to year 3

Antidepressant
medication use
up to year 3

HR (95% CI)
1.26
(1.12-1.41)

HR (95% CI)
1.21
(1.07 - 1.36)

HR (95% CI)
1.33
(1.20 - 1.48)

BMI; adjusted for
propensity score
and baseline
values for other
covariates)
HR (95% CI)
1.31
(1.17 - 1.45)

symptoms, and
BMI; baseline
values for other
covariates)
HR (95% CI)
1.34
(1.20 - 1.50)

Clinical Trial (CT) (N=52,326-the number of patients with complete data for time varying
antidepressant medication use and BMI up until year 3, and baseline values for presence of
elevated depressive symptoms other covariates)
1.17
1.16
1.28
1.26
1.27
(1.04-1.31)
(1.02 - 1.32)
(1.14 - 1.43)
(1.12 - 1.41)
(1.13 - 1.43)
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Table 3. Inverse Probability of Treatment-Weighted Estimates of The Parameters Of A Marginal
Structural Model For The Causal Effect Of Antidepressant Medication Use On Diabetes Risk
(Continued on to next few pages)
Estimate

SE

95% CI

HR (95% CI)

P-value

WHI-OS
Antidepressant
medication use

0.293

0.056

0.185

-

0.402

1.34
(1.20-1.50)

<.0001

-0.580

0.043

-0.664

-

-0.496

0.56
(0.51-0.61)

<.0001

Ethnicity
White
Other

.

Education
<= high school
High school or
GED
>=High school,
but less than 4
years of college
4 or more years
of college
Minutes of
physical activity
per week
Relative had
adult diabetes

0.348

0.076

0.198

-

0.498

0.279

0.051

0.180

-

0.379

1.42
(1.22-1.65)
1.32
(1.20-1.46)

0.294

1.24
(1.14-1.34)

0.214

0.041

0.133

-

<.0001
<.0001

<.0001
.

-0.001

0.000

-0.001

-

0.000

No

-0.388

0.085

-0.554

-

-0.222

Yes

0.397

0.084

0.232

-

0.562

1.00
(0.9991-0.9996)

0.68
(0.57-0.80)
1.49
(1.26-1.75)

Don't know
Hormone therapy
use

<.0001

<.0001
<.0001
.

Never

0.115

0.041

0.034

-

0.196

Former

0.130

0.045

0.041

-

0.219

1.12
(1.03-1.22)
1.14
(1.04-1.24)

Current

0.0053
0.0041
.

Smoking status
Never Smoked

-0.165

0.073

-0.307

-

-0.023

Past Smoker

-0.126

0.074

-0.270

-

0.018

Current Smoker
Presence of
elevated
depressive
symptoms

0.85
(0.74-0.98)
0.88
(0.76-1.02)

0.0227
0.0869
.

0.089

0.045

0.000
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-

0.177

1.09
(1.00-1.19)

0.049

Estimate

SE

95% CI

HR (95% CI)
1.08
(1.08-1.09)
1.02
(1.01-1.02)

BMI

0.080

0.002

0.076

-

0.084

Age
Baseline total
energy intake

0.018

0.003

0.013

-

0.023

4.87- 1100.54

-0.205

0.048

-0.300

-

-0.110

1100.55- 1437.42

-0.238

0.049

-0.333

-

-0.143

1437.44- 1828.01

-0.174

0.048

-0.268

-

-0.080

0.81
(0.74-0.90)
0.79
(0.72-0.87)
0.84
(0.76-0.92)

P-value
<.0001
<.0001

<.0001
<.0001
0.0003

>=1828.02
WHI-CT
Antidepressant
medication use

0.242

0.059

0.126

-

0.357

1.27
(1.13-1.43)

<.0001

-0.462

0.041

-0.542

-

-0.381

0.63
(0.58-0.68)

<.0001

0.315

0.072

0.174

-

0.455

0.196

0.049

0.101

-

0.292

1.37
(1.19-1.58)
1.22
(1.11-1.34)

0.219

0.041

0.139

-

0.298

1.24
(1.15-1.35)

<.0001

-0.001

0.000

-0.001

-

0.000

0.999
(0.999-1.00)

<.0001

No

-0.358

0.075

-0.505

-

-0.210

Yes

0.323

0.074

0.177

-

0.468

Never

0.167

0.045

0.078

-

0.255

Former

0.165

0.049

0.069

-

0.261

Ethnicity
White
Other
Education
<= high school
High school or
GED
>=High school,
but less than 4
years of college
4 or more years
of college
Minutes of
physical activity
per week
Relative had
adult diabetes

0.70
(0.60-0.81)
1.38
(1.19-1.60)

<.0001
<.0001

<.0001
<.0001

Don't know
Hormone therapy
use

Current
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1.18
(1.08-1.29)
1.18
(1.07-1.30)

0.0002
0.0008

Estimate

SE

95% CI

HR (95% CI)

P-value

Never Smoked

-0.186

0.063

-0.310

-

-0.062

Past Smoker

-0.203

0.065

-0.330

-

-0.076

Current Smoker
Presence of
elevated
depressive
symptoms

0.088

0.045

0.000

-

0.176

BMI

0.073

0.002

0.069

-

0.077

Age
Baseline total
energy intake

0.020

0.003

0.015

-

0.025

4.87- 1100.54

-0.037

0.049

-0.133

-

0.059

1100.55- 1437.42

-0.037

0.046

-0.127

-

0.053

1437.44- 1828.01
1828.0223020.93
Participated in
hormone therapy
trial
Participated in
dietary
modification trial
Participated in
calcium/
vitamin D
supplementation

-0.060

0.044

-0.146

-

0.026

0.96
(0.88-1.06)
0.96
(0.88-1.05)
0.94
(0.86-1.03)

0.096

0.052

-0.006

-

0.198

1.10
(0.99-1.22)

0.0656

0.095

0.054

-0.010

-

0.201

1.10
(0.99-1.22)

0.0756

-0.028

0.034

-0.095

-

0.039

0.97
(0.91-1.04)

0.4128

Smoking status
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0.83
(0.73-0.94)
0.82
(0.72-0.93)

1.09
(1.00-1.19)
1.08
(1.07-1.08)
1.02
(1.02-1.03)

0.0033
0.0018

0.0511
<.0001
<.0001

0.4477
0.4167
0.17

Table 4. Estimated Probability of Having One’s Own Observed Treatment History And Censoring
History At Follow-Up

N

Mean

SD

Median

Quartile
Range

Minimum

Maximum

0.92

0.06

0.48

0.99

0.92

0.06

0.36

0.99

WHI-OS
36 Months
Probability of having observed antidepressant medication history
given baseline
64048
0.91
0.05
covariates
given time-varying
64048
0.91
0.06
covariates

Probability of being uncensored
given baseline
64099
covariates
given time-varying
64099
covariates

0.99983

0.0000261

0.9998269

0.0000372

0.99968

0.99988

0.99983

0.0000262

0.9998270

0.0000374

0.99969

0.99988

WHI-CT
12 Months
Probability of having observed antidepressant medication history
given baseline
covariates
46084
0.93
0.04
given time-varying
covariates
46084
0.93
0.05
Probability of being uncensored
given baseline
covariates
46084
given time-varying
covariates
46084

0.95

0.05

0.52

0.99

0.95

0.05

0.31

0.99

0.9999997

6.4192736E-8

0.9999997

8.7696349E-8

0.9999994

0.9999998

0.9999997

6.4550241E-8

0.9999997

8.8088701E-8

0.9999993

0.9999998

0.88

0.10

0.25

0.99

0.88

0.10

0.20

0.99

36 Months
Probability of having observed antidepressant medication history
given baseline
45235
0.86
0.09
covariates
given time-varying
45235
0.86
0.09
covariates
Probability of being uncensored
given baseline
45235
covariates
given time-varying
45235
covariates

0.999971

6.4295277E-6

0.999972

8.8005442E-6

0.99994

0.99998

0.999971

6.4828669E-6

0.999972

8.8476766E-6

0.99993

0.99998
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Table 5. Estimate of Variation in Primary Exposure and Time-Dependent Confounder Variables
(WHI-OS)

Antidepressant use at year 3

Antidepressant use at
baseline
N (%)
3321 (69.35%)

No antidepressant use at
baseline
N (%)
3083 (4.86%)

1468 (30.65%)

60,297 (95.14%)

Presence of elevated
symptoms at baseline

No presence of elevated
symptoms at baseline

4348 (44.34%)

6,333 (10.85%)

5,458 (55.66%)

52,030 (89.15%)

Baseline
Mean (SD)
26.80 (5.54)

Year 3
Mean (SD)
27.09 (5.59)

No antidepressant use at year 3

Presence of elevated symptoms at year 3
No presence of elevated symptoms at
year 3

BMI
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Figure 1. Illustration of time-dependent confounding by BMI in the association of antidepressant
medication use and time to development of diabetes

Measured covariates (L(0))
BMI, race, smoking,
Exposure (A(0))
hormone therapy use
Antidepressant
Medication use
Unmeasured covariates (U(0))

Measured covariates (L(1))
BMI, race, smoking,
hormone therapy use
Exposure (A(1))
Antidepressant
Medication use
Unmeasured covariates (U(1))

Outcome (Y)
Development of
diabetes

Figure 1 illustrates the hypothesis that there is time-varying confounding by BMI with regard to
the association between diabetes risk and antidepressant use. Let A denote the exposure or
antidepressant use, L denotes measured covariates such as BMI or race, U denotes unmeasured
covariates and Y denotes the outcome of development of diabetes. The causal graph in Figure 1
shows that the probability of antidepressant medication use (A) depends on BMI (L), but not U.
There is confounding, but measured covariates are sufficient to adjust for, so no unmeasured
confounding. The probability of antidepressant medication use at baseline (A(0)) is determined
by baseline BMI (L(0)). In our example, confounding is time dependent because antidepressant
medication use vs. non-use at time 1 (A(1)) is determined by previous exposure (A(0)) and BMI
at time 1 (L(1)). Even though antidepressant medication use (A) and diabetes (Y) share common
causes, the non-causal association between exposure and outcome can be blocked by
conditioning on the BMI (L).
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Figure 2. Flow chart describing analytic cohort included for the investigation

161,808 Total

Exclusions:
 377 women without race/ethnicity information
 7,167 women with self-reported DM at baseline (3,902 from the WHI-OS arm and
3,265 from the CT arm respectively).
 145 women missing DM at baseline
154,119 Enrolled
CT arm: 64,706

531 women
missing baseline
depression

8969 women
missing anti
depression
medication at
baseline, 1 year or 3
year followup

2880 women
missing BMI at
baseline, 1 year or 3
year followup

64,175 women
with
nonmissing
information

55,206 women
with
nonmissing
information

OS arm: 89,413

10427 women
missing depression
at baseline or 3 year
followup

78986 women with
nonmissing
depression at baseline
and 3 year visit

4194 women missing
anti depression
medication at
baseline or 3 year
followup

52,326 women
with
nonmissing
information

4171 self reported
diabetes

74792 women
with
nonmissing
information

2705 women
missing BMI at
baseline, 1 year or 3
year followup

72,087 women
with
nonmissing
information

3918 women 3
year visit more
than ½ year from
3 years post
enrollment date

68,169 women 3
year visit within
½ year of 3 year
mark [913-1278
days from
enrollment]

3624 self reported
diabetes
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APPENDIX
SAS CODE TO FIT THE MARGINAL STRUCTURAL COX PROPORTIONAL HAZARDS MODEL

Here I provide details on how to set up the data, along with some SAS code to perform
the Marginal Structural Cox Proportional Hazards analysis. The first part of the analysis uses the
proc logistic procedure to calculate the probability of not being on antidepressants (Models 1
and 2). Data in the file ‘iptw’ contains 1 record per woman for each time point included in the
analysis. For example, in the WHI-OS dataset, we have measurements at baseline and year 3.
Each woman has two records, one for baseline and one for year 3. Next we use the proc logistic
procedure to calculate the probability of not being censored (Models 3 and 4). In the data file
‘iptw2’ the data has been expanded so that a woman has 1 record per month until her time to
diabetes or time to censoring. The dataset ‘main’ merges Models 1-4 together to calculate our
IPTW weights. This again will be an expanded dataset so a woman has 1 record per month until
her time to diabetes or time to censoring. The dataset ‘main_w’ contains the inverse probability
of treatment weights and is the dataset used to run the marginal structural model analysis. Last,
we use the proc genmod procedure to fit the final pooled logistic regression model to obtain the
estimates of our association of interest.
At the baseline time point, the variables in Model 1 are basically a subset of Model2.
Model 1 includes only baseline covariates and Model 2 includes baseline and follow-up values
for the same variables. Because baseline is the start of our analysis, there are no follow-up
values to consider at that time point. For that reason, the weights at baseline are going to be 1
and here we run a logistic regression model estimating the probability of not being on
antidepressants for the follow up (month 36) time point only.
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Antidep is a dichotomous 0/1 indicator of the participant being on or off
antidepressants. Model 1 includes a time-dependent intercept and baseline covariates:
presence of elevated depressive symptoms (base_depression), BMI (base_bmi), Age
(age), Ethnicity (ethnic_cat), Education (educ4), Minutes of physical activity per

week (tminwk), Total energy intake (base_energy_cat), Family history of diabetes
(diabrel), Hormone therapy use (hormstat) and smoking status (smoking). Model

2 includes a time-dependent intercept and baseline covariates, with the addition of the most
recent time-dependent values (depression, bmi).
The outcome variable in Models 3 and 4 is a dichotomous indicator of whether or not
the participant has been censored up to that time point. These models include as regressors
variables for ‘month’ and ‘month2’ to relax the linearity assumption. All available person
months are included. Model 3 includes baseline covariates with the addition of baseline
antidepressant medication use, while Model 4 includes the baseline covariates as well as the
most recent time-dependent value.
We merge Models 1-4 together and in the following data step use the predicted values
from those models to compute our IPTW estimates. First, we calculate the numerator K2_0 and
denominator K1_0 of the probability of not being censored by forming the product up to month
t of the subject-specific values predicted in Models 3 and 4.
We then calculate the numerator K1_0 and denominator K2_0 of the probability of not
being on antidepressants by forming the product up to month t of the subject-specific values
predicted in Models 1 and 2. We multiply by that probability for participants who were not on
antidepressants and 1-that probability for participants who were taking antidepressants from
month 36 until time to diabetes or time to censoring. From baseline until month 35, the
probability of not being on antidepressants is 1. We then use the numerators and denominators
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of the probability of not being censored and the probability of not being on antidepressants to
calculate the ‘stabilized’ (stabw) and ‘non-stabilized’ (nstabw) weights.
In our last step, we use the proc genmod procedure to fit the weighted pooled logistic
model to obtain estimates of our association of interest from our Marginal Structural Cox PH
Model. The outcome here is diabetes_tv which is a dichotomous indicator of whether or not
the participant developed diabetes during that month. The patient ID variable and the
independent working correlation matrix (subject=id/type=ind) must be specified. We weighted
the model used the stabilized weights by using the ‘scwgt stabw’ statement in the procedure.
The ‘estimate’ statement asks the procedure to report the odds ratio for our main association of
interest which we use as our hazard ratio, in addition to the coefficients in the model.

/*calculate probability of not being on antidepressants*/
/* Model 1*/
proc sort data=iptw;
by id month;
run;
proc logistic data=iptw;
class ethnic_cat educ4 base_energy_cat hormstat smoking diabrel;
where month=36;
model antidep=base_depression base_bmi age ethnic_cat educ4 tminwk
base_energy_cat diabrel hormstat smoking;
output out=model1 p=pandep_0_temp;
run;
/* Model 2*/
proc logistic data=iptw;
where month=36;
class ethnic_cat educ4 base_energy_cat energy_cat hormstat smoking
base_energy_cat diabrel;
model antidep=base_depression depression base_bmi bmi age ethnic_cat
educ4 tminwk base_energy_cat diabrel hormstat smoking;
output out=model2 p=pandep_w_temp;
run;

/*calculate probability of not being censored*/
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/* Model 3*/
proc logistic data=iptw2;
class ethnic_cat educ4 base_energy_cat hormstat smoking diabrel;
model censor_tv=antidep depression bmi age ethnic_cat educ4 tminwk
base_energy_cat diabrel hormstat smoking month month_sq;
output out=model3 p=punc_0;
run;
/* Model 4*/
proc logistic data=iptw2;
class ethnic_cat educ4 base_energy_cat hormstat smoking diabrel;
model censor_tv=antidep antidepressant_tv depression bmi age ethnic_cat
educ4 tminwk base_energy_cat diabrel hormstat smoking depression_tv
bmi_tv month month_sq;
output out=model4 p=punc_w;
run;

/*merge data*/
data main;
merge temp1 temp2 model3(in=a) model4(in=b);
by id month; if a=1 and b=1;
if first.id then do;
pandep_0 = 1;
pandep_w = 1;
end;
if month=36 then do;
pandep_0=pandep_0_temp;
pandep_w=pandep_w_temp;
end;
retain pandep_0 pandep_w;
run;

/* Calculate the weights*/
data main_w;
set main;
by id month;
/*reset variables for a new patient*/
if first.id then do;
k2_0=1; k2_w=1;
end;
retain k2_0 k2_w;
/*inverse probability of censoring weights*/
else do;
k2_0=k2_0*punc_0;
k2_w=k2_w*punc_w;
end;
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/* Inverse probability of treatment weights */
if antidepressant_tv=0 and month>=36 then k1_0=pandep_0;
if antidepressant_tv=0 and month>=36 then k1_w=pandep_w;
if antidepressant_tv=1 and month>=36 then k1_0=(1-pandep_0);
if antidepressant_tv=1 and month>=36 then k1_w=(1-pandep_w);
if month<36 then k1_0=1;
if month<36 then k1_w=1;
/* Stabilized and non stabilized weights */
stabw=(k1_0*k2_0)/(k1_w*k2_w);
nstabw=1/(k1_w*k2_w);
run;

/* Pooled logistic regression model to run the MSM analysis */
proc genmod data=main_w descending;
class id ethnic_cat educ4 hormstat smoking base_energy_cat diabrel;
model diabetes_tv=antidepressant_tv ethnic_cat educ4 tminwk diabrel
hormstat smoking depression_tv bmi_tv age base_energy_cat month
month_sq/ link=logit dist=bin;
scwgt stabw;

repeated subject=id/ type=ind;
estimate "log O.R. antidepressant" antidepressant_tv 1 / exp;
run;
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